|
GSK PLC on Wednesday said its drug for metastatic non-squamous non-small cell lung cancer Jemperli, or dostarlimab, is advancing to a phase 3 trial following positive results.
Jemperli is an antibody approved for the treatment of endometrial cancer in the US and EU.
Non-squamous means flat cells do not look like a fish scale under a microscope.
Citing its phase 2 Perla study, the Brentford, west London-based pharmaceuticals firm said that the safety and tolerability profile of dostarlimab was consistent with previous clinical trials of similar regimens.
Further, in its Costar phase 2/3 trial, now advancing to phase 3, GSK stated that the trial met its pre-specified expansion criteria per protocol.
‘These trials support the ambition for dostarlimab to become the backbone of our ongoing immuno-oncology-based research and development programme when used alone and in combination with standard of care and future novel cancer therapies, particularly in patients with currently limited treatment options,’ said Hesham Abdullah, Senior Vice President & Global Head of GSK's Oncology Development arm.
The company will present full results from the Perla phase 2 trial at an upcoming scientific meeting.
GSK shares were 0.9% lower at 1,317.00 pence each in London on Wednesday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
